4,045 Danaher Corporation $DHR Shares Purchased by RDA Financial Network

RDA Financial Network raised its stake in Danaher Corporation (NYSE:DHR) by 166.9% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 6,468 shares of the conglomerate’s stock after acquiring an additional 4,045 shares during the quarter. RDA Financial Network’s holdings in Danaher were worth $1,433,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in the stock. BlackRock Inc. bought a new stake in shares of Danaher during the 2nd quarter valued at approximately $10,492,520,000. Wellington Management Group LLP increased its position in Danaher by 10.4% during the 2nd quarter. Wellington Management Group LLP now owns 16,316,834 shares of the conglomerate’s stock worth $3,108,031,000 after purchasing an additional 1,542,310 shares in the last quarter. Jupiter Topco LLC bought a new position in Danaher in the 2nd quarter valued at approximately $1,456,317,000. Generation Investment Management LLP bought a new position in Danaher in the 2nd quarter valued at approximately $1,287,949,000. Finally, Bank of America Corp DE acquired a new stake in Danaher in the second quarter valued at approximately $993,846,000. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms have weighed in on DHR. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and set a $240.00 target price on shares of Danaher in a research note on Wednesday, July 22nd. Wells Fargo & Company lowered their price target on shares of Danaher from $212.00 to $195.00 and set an “equal weight” rating for the company in a report on Wednesday, July 22nd. Barclays increased their price target on Danaher from $230.00 to $255.00 and gave the company an “overweight” rating in a research note on Wednesday, October 7th. Guggenheim raised their price objective on Danaher from $200.00 to $250.00 and gave the company a “buy” rating in a report on Thursday, October 1st. Finally, Weiss Ratings upgraded Danaher from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, September 16th. Two analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, Danaher currently has an average rating of “Moderate Buy” and a consensus target price of $235.41.

Danaher News Summary

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Danaher and NVIDIA announced an AI collaboration to combine Danaher’s scientific instruments, laboratory workflows, automation technology and software with NVIDIA’s accelerated computing and AI capabilities. The partnership is intended to advance autonomous science and speed drug discovery and other laboratory research. Danaher Collaborates with NVIDIA to Advance Autonomous Science
• Positive Sentiment: Danaher is also preparing to launch its first AI-powered autonomous laboratory, targeted to operate at commercial scale in early 2027. The initiative could support longer-term growth in laboratory automation and strengthen the company’s position in AI-enabled life-science research. How to Invest in AI Drug Discovery
• Positive Sentiment: Multiple Zacks reports say Danaher has a favorable combination of earnings-estimate trends and Earnings ESP, suggesting potential for the company to exceed consensus estimates in its next quarterly report. Danaher has also recently demonstrated earnings momentum, with its latest reported quarter exceeding both EPS and revenue expectations. Will Danaher Beat Estimates Again in Its Next Earnings Report?
• Neutral Sentiment: Danaher is projected to announce earnings on Wednesday. Investors will be watching revenue growth, management’s outlook and whether diagnostics and life-sciences demand support the anticipated improvement in earnings. Danaher Projected to Announce Earnings

Danaher Stock Performance

Danaher stock opened at $231.52 on Friday. The business has a 50 day moving average of $213.55 and a 200-day moving average of $195.74. Danaher Corporation has a 1 year low of $160.93 and a 1 year high of $242.80. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.65 and a quick ratio of 1.25. The company has a market capitalization of $162.76 billion, a P/E ratio of 41.12, a P/E/G ratio of 2.82 and a beta of 0.76.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Monday, July 20th. The conglomerate reported $1.94 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.85 by $0.09. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The business had revenue of $6.26 billion during the quarter, compared to analyst estimates of $6.12 billion. During the same quarter last year, the business earned $0.77 EPS. The firm’s quarterly revenue was up 5.5% on a year-over-year basis. On average, equities research analysts predict that Danaher Corporation will post 8.53 earnings per share for the current year.

Danaher Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be given a $0.40 dividend. This represents a $1.60 annualized dividend and a yield of 0.7%. The ex-dividend date is Wednesday, September 30th. Danaher’s dividend payout ratio is 28.42%.

Danaher Company Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.